| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 8,315 | 44,854 | 8,955 | 17,084 |
| Sales and marketing | NaN | NaN | 2,906 | 3,009 |
| Research and development | 46,662 | 50,092 | 55,028 | 39,213 |
| Sales, general and administrative | NaN | 25,976 | 22,052 | 18,977 |
| Sales, general, and administrative | 12,334 | NaN | NaN | NaN |
| Depreciation, amortization, and impairment | NaN | -2,634 | 5,247 | 5,470 |
| Depreciation and amortization | 6,838 | NaN | NaN | NaN |
| Total operating expenses | 65,834 | 73,434 | 85,233 | 66,669 |
| Loss from operations | -57,519 | -28,580 | -76,278 | -49,585 |
| Other (note 15) | NaN | -156 | -1,984 | 1,957 |
| Interest and other | 3,643 | 5,921 | 6,765 | 7,592 |
| Grants and incentives | 4,339 | 3,316 | 2,729 | 3,692 |
| Total other income | 7,982 | 9,081 | 7,510 | 13,241 |
| Loss before income tax | -49,537 | -19,499 | -68,768 | -36,344 |
| Income tax recovery | -6,372 | -10,554 | -11,649 | -1,617 |
| Net loss | -43,165 | -8,945 | -57,119 | -34,727 |
| Foreign currency translation adjustment | 1,815 | -1,536 | -41 | 4,341 |
| Comprehensive loss | -41,350 | -10,481 | -57,160 | -30,386 |
| Basic EPS | -0.14 | -0.035 | -0.19 | -0.12 |
| Diluted EPS | -0.14 | -0.035 | -0.19 | -0.12 |
| Basic Average Shares | 303,074,605 | 299,751,890 | 298,875,174 | 298,508,601 |
| Diluted Average Shares | 303,074,605 | 299,751,890 | 298,875,174 | 298,508,601 |
AbCellera Biologics Inc. (ABCL)
AbCellera Biologics Inc. (ABCL)